Advertisement

Topics

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-03-10. This 288-page report is available in PDF from $2000.

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015’, provides an overview of the Recurrent Glioblastoma Multiforme (GBM)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Recurrent Glioblastoma Multiforme (GBM)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Recurrent Glioblastoma Multiforme (GBM) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Recurrent Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Recurrent Glioblastoma Multiforme (GBM) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and…

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Recurrent Glioblastoma Multiforme (GBM) Overview 8
Therapeutics Development 9
Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Overview 9
Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis 10
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 11
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 15
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Recurrent Glioblastoma Multiforme (GBM) - Products under Development by Companies 19
Recurrent Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 22
Recurrent Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 23
Agenus, Inc. 23
Amgen Inc. 24
AngioChem Inc. 25
Apogenix GmbH 26
AstraZeneca PLC 27
Axelar AB 28
Boehringer Ingelheim GmbH 29
Boston Biomedical, Inc. 30
Celldex Therapeutics, Inc. 31
e-Therapeutics plc 32
Eisai Co., Ltd. 33
Eli Lilly and Company 34
EnGeneIC Ltd 35
ERC Belgium SA 36
GenSpera, Inc. 37
GlaxoSmithKline plc 38
GW Pharmaceuticals plc 39
ImmunoCellular Therapeutics, Ltd. 40
Karyopharm Therapeutics, Inc. 41
Merck & Co., Inc. 42
Novartis AG 43
OncoEthix SA 44
Ono Pharmaceutical Co., Ltd. 45
Pfizer Inc. 46
Sangamo BioSciences, Inc. 47
Spectrum Pharmaceuticals, Inc. 48
Threshold Pharmaceuticals, Inc. 49
Tocagen Inc. 50
Vascular Biogenics Ltd. 51
Virttu Biologics Limited 52
ZIOPHARM Oncology, Inc. 53
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Target 56
Assessment by Mechanism of Action 60
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 67
(GWP-42002 + GWP-42003) - Drug Profile 67
Ad-RTS-IL-12 - Drug Profile 68
afatinib - Drug Profile 70
AMG-595 - Drug Profile 74
ANG-1005 - Drug Profile 76
APG-101 - Drug Profile 78
axitinib - Drug Profile 80
AXL-1717 - Drug Profile 83
AZD-7451 - Drug Profile 85
BBI-608 - Drug Profile 86
BGJ-398 - Drug Profile 89
bosutinib - Drug Profile 90
buparlisib hydrochloride - Drug Profile 92
capmatinib - Drug Profile 96
dacomitinib - Drug Profile 98
Dendritic Cell Therapy for Recurrent Glioblastoma Multiforme - Drug Profile 100
DNX-2401 - Drug Profile 101
doxorubicin - Drug Profile 103
ERC-1671 - Drug Profile 104
erismodegib - Drug Profile 106
ETS-2101 - Drug Profile 109
evofosfamide - Drug Profile 111
G-200 - Drug Profile 118
galunisertib - Drug Profile 120
golvatinib + lenvatinib - Drug…

For more information open Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015.

SKU: GMDHC6256IDB

Original Article: Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...